× Industry Reports Services Press Release Contact us About us

Europe Antiviral Drugs Market Size By Age Group (Pediatric, Adult, Geriatric), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), Research Report, Country Outlook (Germany, UK, France, Italy, Spain, Russia, Poland, Netherlands, Sweden, Switzerland), Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 – 2027
Published Date: March 2021 | Publisher: Graphical Research Report ID: GR1737 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Europe anti-viral drugs industry summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 - 2027

3.3    Major factor analysis

3.3.1    Growth drivers

3.3.1.1    Increasing prevalence of viral infection

3.3.1.2    Presence of large geriatric population

3.3.1.3    Increasing research and development activities in the field of Anti-viral drugs

3.3.2    Industry pitfalls and challenges

3.3.2.1    Rising awareness about preventive drug treatment

3.3.2.2    Presence of generics

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Europe Anti-viral Drugs Market, By Drug Class

4.1    Market trends

4.2    DNA Polymerase Inhibitors

4.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.3    Reverse Transcriptase Inhibitors

4.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.4    Protease Inhibitors

4.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.5    Neuraminidase Inhibitors

4.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.6    Others

4.6.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 5   Europe Anti-viral Drugs Market, By Indication

5.1    Market trends

5.2    Influenza

5.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.3    HIV AIDS

5.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.5    Herpes Simplex Virus (HSV)

5.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.6    Coronavirus infection

5.6.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.7    Others

5.7.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 6   Europe Anti-viral Drug Market, By Type

6.1    Market trends

6.2    Branded

6.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.3    Generic

6.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 7   Europe Anti-viral Drugs Market, By Age Group

7.1    Market trends

7.2    Adult

7.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

7.4    Geriatric

7.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 8   Europe Anti-viral Drugs Market, By Country

8.1    Market trends

8.2    Germany

8.2.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.2.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.2.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.2.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.3    UK

8.3.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.3.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.3.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.3.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.4    France

8.4.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.4.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.4.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.4.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.5    Spain

8.5.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.5.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.5.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.5.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.6    Italy

8.6.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.6.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.6.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.6.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.7    Russia

8.7.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.7.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.7.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.7.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.8    Poland

8.8.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.8.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.8.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.8.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.9    Switzerland

8.9.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.9.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.9.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.9.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.10    The Netherlands

8.10.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.10.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.10.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.10.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.11    Sweden

8.11.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.11.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.11.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.11.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Gilead Science, Inc

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Drug class landscape

9.1.4    Strategic outlook

9.2    Johnson & Johnson

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Drug class landscape

9.2.4    Strategic outlook

9.3    AstraZeneca

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Drug class landscape

9.3.4    Strategic outlook

9.4    GlaxoSmithKline

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Drug class landscape

9.4.4    Strategic outlook

9.5    Abbvie, Inc

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Drug class landscape

9.5.4    Strategic outlook

9.6    Merck & Co.,

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Drug class landscape

9.6.4    Strategic outlook

9.7    Bristol Myers Squib

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Drug class landscape

9.7.4    Strategic outlook

9.8    Mylan N.V.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Drug class landscape

9.8.4    Strategic outlook
 


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]